President Trump's December 2025 executive order directed the Attorney General to expedite rescheduling marijuana from Schedule I to Schedule III under the Controlled Substances Act, building on HHS's 2023 scientific recommendation and DEA's prior proposed rulemaking. However, four months later, the process lingers in limbo under new DEA Administrator Terry Cole and Attorney General Pam Bondi, with no final rule published despite incorporating 43,000 public comments. Recent pressure includes Democratic Rep. Steve Cohen's March 27 letter demanding a timeline from DOJ and DEA heads, and a DOJ statement indicating the final phase post-agency review. Traders monitor for Federal Register notice amid procedural delays and shifting administrative priorities, with no firm resolution date announced.
Experimental AI-generated summary referencing Polymarket data. This is not trading advice and plays no role in how this market resolves. · Updated$310,094 Vol.

June 30
18%

December 31
38%
$310,094 Vol.

June 30
18%

December 31
38%
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
Market Opened: Feb 7, 2026, 5:04 PM ET
Resolver
0x65070BE91...The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
Resolver
0x65070BE91...President Trump's December 2025 executive order directed the Attorney General to expedite rescheduling marijuana from Schedule I to Schedule III under the Controlled Substances Act, building on HHS's 2023 scientific recommendation and DEA's prior proposed rulemaking. However, four months later, the process lingers in limbo under new DEA Administrator Terry Cole and Attorney General Pam Bondi, with no final rule published despite incorporating 43,000 public comments. Recent pressure includes Democratic Rep. Steve Cohen's March 27 letter demanding a timeline from DOJ and DEA heads, and a DOJ statement indicating the final phase post-agency review. Traders monitor for Federal Register notice amid procedural delays and shifting administrative priorities, with no firm resolution date announced.
Experimental AI-generated summary referencing Polymarket data. This is not trading advice and plays no role in how this market resolves. · Updated


Beware of external links.
Beware of external links.
Frequently Asked Questions